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Abstract: The gut microbiota plays a pivotal role in immune system development and function.
Modification in the gut microbiota composition (dysbiosis) early in life is a critical factor affecting the
development of food allergy. Many environmental factors including caesarean delivery, lack of breast
milk, drugs, antiseptic agents, and a low-fiber/high-fat diet can induce gut microbiota dysbiosis,
and have been associated with the occurrence of food allergy. New technologies and experimental
tools have provided information regarding the importance of select bacteria on immune tolerance
mechanisms. Short-chain fatty acids are crucial metabolic products of gut microbiota responsible for
many protective effects against food allergy. These compounds are involved in epigenetic regulation
of the immune system. These evidences provide a foundation for developing innovative strategies to
prevent and treat food allergy. Here, we present an overview on the potential role of gut microbiota
as the target of intervention against food allergy.
Keywords: cow’s milk allergy; diet; immune tolerance; dysbiosis; probiotics; short chain fatty
acids; butyrate
1. Introduction
During the last several decades, a changing patterns in the epidemiology of food allergy [FA]
have been observed, with an increased prevalence, severity of clinical manifestations, and risk of
persistence until later ages [1]. Atopic family history, ethnicity, atopic dermatitis (AD), and related
genetic polymorphisms have been associated with FA development [2]. Although genetic factors may
predispose individuals to the development of FA among selected individuals, they cannot explain the
changes in epidemiology over this short time frame, suggesting that environmental factors promote
FA [3]. FA develops following loss of immune tolerance, which results in allergic sensitization and
subsequent disease manifestation and progression.
The initial exposure to food allergens occurs predominantly via the gastrointestinal tract or skin.
An impaired skin barrier could lead to increased transcutaneous passage of antigens and subsequent
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sensitization. An association between the early onset of AD and development of FA has been shown [4].
In the gastrointestinal tract, the two main factors influencing immune tolerance are dietary factors and
microbiota composition and function [5]. Kim et al. demonstrated that under normal physiological
conditions, macromolecules from the diet induce the bulk of regulatory T cells (Tregs) development,
which is essential for suppressing a default immune response to dietary antigens [5]. Observational
studies have suggested that the early introduction of peanut [6], egg [7], or cow’s milk [8] may prevent
the development of allergy to these foods. A randomized controlled trial (Learning Early about
Peanut Allergy, LEAP) showed that the early consumption of peanut in high-risk infants with severe
eczema, egg allergy, or both reduced the development of peanut allergy by 80% by 5 years of age [9].
The Persistence of Oral Tolerance to Peanut (LEAP-On) study showed that the absence of reactivity is
maintained in these subjects [10].
The gut microbiota could be defined as the trillions of microbes that collectively inhabit the gut
lumen [4,11], and increasing evidence shows that altered patterns of microbial exposure [dysbiosis]
early in life can lead to FA development by negatively influencing immune system development [12].
Thus, the gut microbiota could be considered a potential target for preventive and therapeutic
intervention against FA. Recent studies have reported the efficacy of intervention in the gut microbiota
against FA.Here, we review the current understanding of the potential role of gut microbiota as
potential target against FA.
2. Importance of Microbial Exposure for the Development of Immune Tolerance
Immune tolerance is the state of unresponsiveness of the immune system to substances or
tissues that have the potential to induce an immune response. Tolerance is achieved through both
central tolerance and peripheral tolerance mechanisms [13]. The exact mechanisms involved in the
development of immune tolerance have not been not fully defined [14]. Current evidence suggests
that the gut microbiota and its metabolites (mainly short chain fatty acids), together with to exposure
to dietary factors in early life, critically influence the establishment of immune tolerance to food
antigens [5] (Figure 1). Germ-free mice are unable to achieve immune tolerance to food antigens [15].
During the early stage of post-natal life, development of the gut microbiota parallels maturation
of the immune system [16]. During vaginal delivery, infants receive their first bacterial inoculum
from the maternal vaginal tract, skin tissue, and often fecal matter, exposing the immature immune
system of newborns to a significant bacterial load [17]. Maturation of a healthy gut microbiota in early
life allows for a change in the Th2/Th1 balance, favoring a Th1 cell response [18], while dysbiosis
alters host-microbiota homeostasis, favoring a shift in the Th1/Th2 cytokine balance toward a Th2
response [19]. Gut microbes induce the activation of Tregs which are depleted in germ-free mice [20].
Microbiota-induced Tregs express the nuclear hormone receptor RORγt and differentiate along a
pathway that also leads to Th17 cells; while in the absence of RORγt in Tregs, there is an expansion
of GATA-3-expressing Tregs, as well as conventional Th2 cells, and Th2-associated pathology is
exacerbated [21]. Moreover, it has been demonstrated that under normal physiological conditions,
macromolecules obtained via the diet induce Treg cell development in the small intestinal lamina
propria, which is essential for suppressing the default strong immune response to dietary antigens [5].
The presence of both diet- and microbe-induced populations of Treg cells may be required to induce
complete tolerance to food antigens [5].
It has been speculated that microbiota can activate MyD88 signaling in the lamina propria and
follicular dendritic cells (DCs) [22]. Mucosal plasma cells, upon induction by DCs, produce secretory
IgA (sIgA). The sIgA system is considered important in the pathogenesis of FA. Delayed development
of IgA-producing cells or insufficient sIgA-dependent function at the intestinal surface barrier appears
to contribute substantially to FA [21]. This agrees with previous study of minor dysregulations of
both innate and adaptive immunity (particularly low levels of IgA) in children with multiple FAs [23].
Furthermore, the gut microbiota stimulates DCs in the Peyer’s patches to secrete transforming growth
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factor (TGF)-β, C-X-C motif chemokine ligand 13, and B-cell activating protein, which leads to IgA
production and class switching [24].Nutrients 2017, 9, 672 3 of 11 
 
 
Figure 1. Immune tolerance network in the intestinal lumen: interaction between microbiome and 
the gut immune system in early-life. The immune tolerance network is mainly composed by the 
well-modulated activity of different components: gut microbiota (without gut microbiota, it is not 
possible to achieve oral tolerance); dietary factors (mainly dietary peptides, as amino acids are 
unable to drive immune tolerance); epithelial cells; dendritic cells; and regulatory T cells. Food 
antigens and intestinal microbiota constitute the majority of the antigen load in the intestine. 
CX3CR1+ cells (likely macrophages) extend dendrites between intestinal epithelial cells, sample 
antigens in the gut lumen, and transfer captured antigens via gap junctions to CD103+CCR7+ 
dendritic cells (DCs). This subset of DCs migrates from the lamina propria to the draining lymph 
nodes, where the DCs express transforming growth factor-β (TGFβ), retinoic acid (RA), 
interleukin-10 (IL-10) and also express the enzyme indoleamine 2,3-dioxygenase (IDO), thereby 
inducing naïve CD4+ T cells to differentiate into regulatory T (Treg) cells. Macrophages also appear 
to secrete IL-10, leading to Treg cell proliferation. Treg cell express integrin α4β7, which results in 
homing to the gut where Treg cells may dampen the immune response. CD103+ DCs also sample 
antigens that pass through the epithelial barrier via M cell-mediated transcytosis or by extending a 
process through a transcellular pore in an M cell. Recent evidence suggests a role for regulatory B 
cells in activating Tregs after stimulation with microbial factors recognized by Toll-like receptors. B 
cell clones expressing antibodies specific for food allergen may undergo isotype switching in 
secondary lymphoid organs with the aid of follicular T helper (TFH) cells. Food tolerance is 
associated with IgA. For a broader prospective, the complex interaction between intestinal contents 
and immune and non-immune cells creates an environment that favors tolerance by the inducting 
IgA antibodies and Tregs, which produce IL-10, a molecule crucial for the induction of tolerance to 
food antigens. 
Accordingly, it has been recently demonstrated that dietary elements, including fibers and 
vitamin A, are essential for the tolerogenic function of CD103+ DCs and maintenance of mucosal 
Figure 1. Im une tolerance network in the intestin l l : i teraction betw en microbiome and
the gut im une system in early-life. The i e t lera ce network is mainly composed by the
well-modulated activity of different components: gut icrobiota (without gut microbiota, it is not
possible to achieve oral tolerance); dietary factors (mainly dietary peptides, as amino acids are unable
to drive immune tolerance); epithelial cells; dendritic cells; and regulatory T cells. Food antigens
and intestinal microbiota constitute the majority of the antigen load in the intestine. CX3CR1+ cells
(likely macrophages) extend dendrites between intestinal epithelial cells, sample antigens in the gut
lumen, and transfer captured antigens via gap junctions to CD103+CCR7+ dendritic cells (DCs). This
subset of DCs migrates from the lamina propria to the draining lymph nodes, where the DCs express
transforming growth factor-β (TGFβ), retinoic acid (RA), interleukin-10 (IL-10) and also express the
enzyme indoleamine 2,3-dioxygenase (IDO), thereby inducing naïve CD4+ T cells to differentiate into
regulatory T (Treg) cells. Macrophages also appear to secrete IL-10, leading to Treg cell proliferation.
Treg cell express integrin α4β7, which results in homing to the gut where Treg cells may dampen the
immune response. CD103+ DCs also sample antigens that pass through the epithelial barrier via M
cell-mediated transcytosis or by extending a process through a transcellular pore in an M cell. Recent
evidence suggests a role for regulatory B cells in activating Tregs after stimulation with microbial
factors recognized by Toll-like receptors. B cell clones expressing antibodies specific for food allergen
may undergo isotype switching in secondary lymphoid organs with the aid of follicular T helper (TFH)
cells. Food tolerance is associated with IgA. For a broader prospective, the complex interaction between
intestinal contents and im une and non-immune cells creates an environment that favors tolerance by
the inducting IgA antibodies and Tregs, which produce IL-10, a molecule crucial for the induction of
tolerance to food antigens.
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Accordingly, it has been recently demonstrated that dietary elements, including fibers and vitamin
A, are essential for the tolerogenic function of CD103+ DCs and maintenance of mucosal homeostasis,
including IgA production and epithelial barrier function [25].Moreover, in experimental studies, some
mice are protected from the development of FA (non-responders) compared with animals showing
marked systemic FA symptoms after immunizations [26,27]. This differential immune response is
associated with a distinct microbiota composition in mice with a non-responding phenotype [28].
Recent findings have also suggested that neonatal gut microbiome dysbiosis promotes CD4+ T cell
dysfunction associated with allergy [29] and supports age-sensitive interactions with microbiota [30].
Early-life may be a key “window of opportunity” for intervention given the age-dependent association
of the gut microbiome and FA outcomes [31].The microbiota also promotes B cell receptor editing
within the lamina propria upon colonization [32]. Regulatory B (Breg) cells are characterized by
their immunosuppressive capacity, which is often mediated by interleukin (IL)-10 secretion, but also
IL-35 and TGF-β production [33]. An additional immunoregulatory role is the up-regulation of IgG4
antibodies during differentiation to plasma cells. Several studies have demonstrated a potential role
for Breg in the induction and maintenance of the tolerance mechanism [34–36]. Several types of Bregs
with distinct phenotypic characteristics and mechanisms of suppression have been described [34–36];
therefore, additional studies are necessary to understand the effective role of Bregs in oral tolerance.In
addition, there is a body of data reporting the activation of non-immune pathways in food oral
tolerance. Data suggest that a healthy gut microbiota may protect against allergic sensitization
by affecting enterocyte function and regulating its barrier-protective properties. Similarly, innate
lymphoid cells (ILCs) that are abundant in mucosal and barrier sites are involved in these defence
mechanisms [37]. While several subsets of ILCs have been identified, particular attention has been
given to ILC3 and its interactions with the microbiota. Among other factors, these cells produce IL-22,
a cytokine of central importance in maintaining tissue immunity and physiology via its pleiotropic
action in promoting antimicrobial peptide production, enhancing epithelial regeneration, increasing
mucus production, and regulating intestinal permeability [38]. How the microbiota affects the turnover
of ILC3 remains unclear, but recent evidence supports that defined commensals preferentially impact
this subset. Particularly, Clostridia-induced IL-22 has been demonstrated to be an innate mechanism
by which the microbiota can regulate the permeability of the epithelial barrier and contribute to
protection against food allergen sensitization [15]. In contrast, gut microbiota dysbiosis induces
alterations in intestinal epithelial function resulting in aberrant Th2 responses toward allergic, rather
than tolerogenic, responses [39].
3. Gut Microbiota in FA
Epidemiological studies have established a correlation between factors that disrupt the microbiota
during childhood and immune and metabolic conditions later in life. Several factors responsible for
dysbiosis have been associated with the occurrence of FA, such as caesarean delivery [40], lack of breast
milk [41], drug use (mainly antibiotics and gastric acidity inhibitors) [42], antiseptic agent use, and low
fiber/high fat diet [43] (Figure 2). Emerging data from human studies link the use of antimicrobial
agents to the increasing prevalence of FA. Neonatal antibiotic treatment reduced microbial diversity
and bacterial load in both fecal and ileal samples and enhanced food allergen sensitization [15]. Even
low-dose early-life antibiotic exposure can lead to long-lasting effects on metabolic and immune
responsiveness [44]. Maternal use of antibiotics before and during pregnancy, as well as antibiotic
courses during the first months of life, are associated with an increased risk of cow’s milk allergy
(CMA) in infants [45].
Data characterizing the microbiota of patients with FA are still preliminary because of multiple
environmental stimuli that profoundly influence the composition of the gut microbiota [46]. Some
studies have failed to identify differences in infant microbiota according to later allergic status, or
have found different changes in gut microbiota depending on the cases and groups of subjects.
Although compelling evidence for the association of gut microbiota dysbiosis with FA is emerging,
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heterogeneities in study design, including sampling time points, methods used to characterize the
microbiota, and different allergic phenotypes under study, make it difficult to establish a clear
correlation between specific bacterial taxa and allergy development. To better identify microbiota
changes associated with the emergence of FA, well-phenotyped birth cohorts are needed with long-term
follow up.
First studies using bacterial cultures showed that infants allergic to cow’s milk had higher total
bacteria and anaerobic counts [47]. There was no association between culturable bacteria and food
sensitization by 18 months of age in three cohorts of European infants [48]. Kendler et al. found no
association between culturable gut bacteria and sensitization to food including milk, egg, peanut,
and hazelnut [49].Pyrosequencing technology can identify approximately 80% more bacteria in the
gut than those identified by conventional culture-based methods, revealing the high complexity
and diversity of the gut microbiota.Recent evidence suggests that gut dysbiosis precedes FA and
influences during early life affected the subsequent development of allergic disease [50]. Nakayama et
al. profiled the fecal bacteria compositions of allergic and non-allergic infants and correlated changes
in gut microbiota composition with allergy development in later years [51]. They found that in
the allergic group, the genus Bacteroides at 1 month and genera Propionibacterium and Klebsiella at 2
months were more abundant, while the genera Acinetobacter and Clostridium at 1 month were less
abundant than in the non-allergic group [51]. Additionally, the relative abundance of total Proteobacteria,
excluding genus Klebsiella, was significantly lower in the allergic than in the non-allergic group at
the age of 1 month. Allergic infants with high colonization of Bacteroides and/or Klebsiella showed
less colonization of Clostridium within the major phylotypes, suggesting antagonism between these
bacterial groups in the gut. Bacteroides are sensitive to short-chain fatty acids (SCFAs), particularly
under low pH conditions [52], suggesting that the observed antagonism is attributable to an SCFA
produced by Clostridium [52]. Azad et al. found that an increased Enterobacteriaceae/Bacteroidaceae ratio
and low Ruminococcaceae (Clostridia class) abundance, in the context of low gut microbiota richness in
early infancy, are associated with subsequent food sensitization, suggesting that early gut dysbiosis
contributes to subsequent development of FA [53]. A low level of microbial diversity with reduced
Clostridiales, and increased Bacteroidales have been also observed in the gut microbiota of allergic
patients [54].
Cross-sectional studies comparing the intestinal microbial composition of food allergies in healthy
subjects have also been performed. Fecal microbial composition was assessed using 16 S rRNA
sequencing to determine the differences between children with FA (n = 17 with IgE-mediated FA,
n = 17 with non-IgE-mediated FA) and healthy controls (n = 45) [55]. There was no difference in
microbial diversity between groups. Subjects with IgE-mediated FA showed increased levels of
Clostridium sensu stricto and Anaerobacter (Clostridia class) and decreased levels of Bacteroides and
Clostridium XVIII. Levels of C. sensu stricto were also correlated with the levels of IgE [56]. Chen et al.
recently showed that children with food sensitization in early life have an altered fecal microbiota and
lower microbiota diversity compared to healthy controls. Children with food sensitization showed
significantly decreased numbers of Bacteroidetes and a significantly increased number of Firmicutes
compared to healthy children. The most differentially abundant taxa in children with food sensitization
were characterized by increased abundances of Clostridium IV and Subdoligranulum (Clostridia class)
and decreased abundances of Bacteroides and Veillonella (Clostridia class) [56]. Recently, enriched taxa
from the Clostridia class and Firmicutes phylum were observed in children with a more favourable
CMA disease course [57]. Accordingly, a low abundance of some sub-taxa belonging to Clostridia may
be associated with the development of FA. The Clostridia class has become one of the largest genera of
bacteria, and presently contains more than 100 species. Some Clostridia groups possess pathogenic
species; however, most Clostridia have a commensal relationship with the host [58].In agreement with
this view, a pivotal study by Atarashi et al. showed that the spore-forming component of gut microbiota,
particularly clusters IV and XIVa of the genus Clostridium, promoted Tregs accumulation in the colonic
mucosa. Colonization of mice by a defined mix of Clostridium strains provided an environment rich
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in TGF-β and affected the number and function of colonic Tregs expressing the Foxp3 transcription
factor (Foxp3+ Tregs) [59]. Foxp3+ Tregs play a critical role in oral tolerance [60]. In a subsequent study,
Atarashi et al. isolated 17 strains within Clostridia clusters XIVa, IV and XVIII from a human fecal
sample and demonstrated that these strains affect Tregs differentiation, accumulation and function in
mouse colon [61].
Many bacterial metabolites are an important communication tools between the host immune
system and commensal microbiota, establishing a broad basis for mutualism [62]. Among these,
SCFAs are among the most abundant, and play a critical role in mucosal integrity, and local and
systemic metabolic function, and stimulate regulatory immune responses [63–65]. Clostridia species
belonging to cluster IV and XIVa are prominent source of SCFAs in the colon. SCFAs have been
implicated in the regulation of both the proportions and functional capabilities of colonic Tregs [62],
which, in some studies, has been specifically attributed to butyrate production by spore-forming
Clostridiales [63]. Moreover, SCFAs can increase epithelial barrier functions, as measured by fluorescein
isothiocyanate-dextran permeability assay, in a GPR43-dependent manner [25] or through the
stabilization of hypoxia-inducible factor-alpha, particularly by butyrate [66]. Therefore, SCFAs can
promote the barrier functions of the intestine, suggesting another protective role of butyrate against FA.
In FA children compared to healthy subjects, different levels of fecal SCFAs, particularly butyrate, have
been described [67–69]. As recently demonstrated, dysbiosis in Faecalibacterium prausnitzii is associated
with AD, but it was shown that the presence of subspecies is more associated with AD than with
the species overall [70]. Dysbiosis results in the suppression of high-butyrate-producer subspecies,
leading to a reduction in overall butyrate production. Thus, different types of dysbiosis may share the
same metabolic features leading to similar effects in term of SCFAs or of other metabolites levels that
could facilitate the occurrence of FA. Interestingly, substantial correlations exist between the 16S rRNA
profile, predicted metagenome, and metabolome of neonatal fecal samples, indicating a deterministic
relationship between the bacterial community composition and metabolic microenvironment of the
neonatal gut [29].It is also crucial that studies move beyond cataloguing of bacteria and toward
functional characterization and mechanistic understanding. Metatranscriptomic studies will provide
information regarding not only which bacteria and bacterial genes are present in a sample, but also
the transcriptional activity of the community [71]. Metabolomics can reveal how bacterial metabolites
facilitate interactions with the host and how they may influence the health state of the host [72,73].
Fine-level characterization of bacterial species can help reveal the function of the microbiome, which
is affected by interactions among closely related bacteria that may compete for the same niche but
have distinct activities. Together, these studies will provide a high-resolution picture of bacteria-host
interactions that can lead to disease.Moreover, studies on germ-free mice may enable more precise
determination of how microbial imbalances result in disease.
4. Modulation of the Gut Microbiota in FA
Primary prevention via microbiota-directed therapy is particularly appealing for potentially
decreasing the incidence of FA. Children exposed to farm environments show a decreased risk for the
development of allergic disease [74,75]. Although it has not been proven, a plausible explanation for
the protective effect of early-life farm exposure is the role of microbiota, as individuals exposed to a
farm environment exhibit a different microbial composition than those with other lifestyles [76]. Other
epidemiologic factors protective against FA include having older siblings and pet exposure in early
life [77]. Pet ownership is associated with a high microbial diversity in the home environment [78].
A recent study examining the influence of dietary patterns on the development of FA at the age
of two years suggests that dietary habits influence FA development by changing the composition
of the gut microbiota [43]. During infancy, breast milk provides various benefits to the new-born.
Oligosaccharides, which are enriched in breast milk, favour the colonization of the SCFA-producing
bacteria Bifidobacterium spp. [79]. Breast milk plays a critical role in the maturation of the gut
microbiota by providing an initial source of commensal bacteria to the infant [80]. It has been recently
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demonstrated that higher levels of TGF-β2 in breast milk are associated with an increased relative
abundance of several bacteria, including members of Streptococcaceae and Ruminococcaceae, and lower
relative abundance of distinct Staphylococcaceae taxa [81]. One intervention that can modify the gut
microbiota most significantly is diet, either by introducing new species or bacterial genes or by
modulating the abundance of existing microbes in the community [82]. It has been demonstrated that
an infant diet consisting of high levels of fruits, vegetables, and home-prepared foods was associated
with fewer FA [43] (Figure 2). A high-fiber diet favours the outgrowth of bacteria capable of fermenting
dietary fibers, such as Bifidobacterium and Lactobacillus, followed by an increase in serum SCFA levels.
Neonatal prebiotic supplementation studies have failed to demonstrate any effect of prebiotics on the
development of FA, but showed positive results for other allergic manifestations such as eczema [83].
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tolerance-inducing probiotic-supplemented formula to that obtained from infants receiving EHCF
alone, we found significant positive correlations between the abundance of butyrate-producing genera,
and an increase concentration of fecal butyrate [68]. The mechanisms of action of butyrate are multiple,
but many of these involve epigenetic regulation of gene expression by inhibiting histone deacetylase
(HDAC). Inhibition of HDAC 9 and 6 increased FoxP3 gene expression, and the production and
suppressive function of Tregs [92]. We demonstrated that the use of EHCF+LGG induces stronger
epigenetic regulation of Th1 and Th2 cytokines genes as revealed by the significantly different levels of
promoter region methylation [93]. Similar results were obtained by examining the FoxP3 Treg-specific
demethylated region (TSDR) methylation profile. FoxP3 TSDR demethylation and expression were
significantly higher in children treated with EHCF+LGG compared to in children treated with other
dietary strategies [94]. These results strongly suggest that acting on gut microbiota composition and
function can have long-term protective effects in children with FA.
5. Conclusions
Our understanding of the role of gut microbiota in the development of FA continues to evolve.
Larger studies, preferably longitudinal birth cohort studies with more homogenous designs, are
needed to clarify the presence or absence of a defined dysbiotic signature associated with FA.
In addition, larger interventional trials are required to evaluate the roles of different probiotic strains
in modulating gut microbiota composition and function. Integrating these findings with epigenetics
and metabolomics data enable the development targeted microbiota with innovative approaches to
prevent and manage FA.
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